ZNTL
Zentalis Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.30
+7.98%Year over year
Reported trailing growth
- Revenue
- -100.0%
- EBITDA
- -2.5%
- EBIT
- -4.5%
- EPS
- -8.4%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +37.6%
- EPS
- +15.8%
Three-year CAGR
- Revenue
- -100.0%
- EBITDA
- +22.5%
- EBIT
- +20.1%
- Net income
- +17.4%
- EPS
- +18.0%
- Free cash flow
- +26.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026